Short answer

Rapamycin (sirolimus) is not an approved or proven treatment for depression.
However, it is being studied because of its effects on the mTOR pathway, inflammation, and neuroplasticity. Evidence is early, mixed, and mostly experimental.

Below is a careful research summary with citations.

Research summary: rapamycin and depression
1) Why scientists became interested in rapamycin

Rapamycin is an mTOR inhibitor used as an immunosuppressant (e.g., transplant medicine).
Researchers became interested because:

The mTOR signaling pathway is strongly implicated in depression biology and antidepressant response.

Rapid antidepressants like ketamine appear to work partly by activating mTOR and synaptic plasticity.

This created a paradox:

If mTOR activation helps depression, why study an mTOR inhibitor?

The answer: rapamycin also affects inflammation, autophagy, and synapse stability, which may influence depression differently than simple mTOR activation.

2) Animal research: antidepressant-like effects in mice

Several preclinical studies suggest rapamycin can reduce depression-like behavior in animals.

Examples:

Chronic stress mice show depressive behavior and reduced brain myelination.

Rapamycin prevented depressive behavior and improved myelination in the prefrontal cortex.

Earlier rodent studies found antidepressant-like activity in forced swim and tail suspension tests.

Interpretation:

Suggests possible antidepressant mechanisms.

But animal models often fail to translate to humans.

3) Human clinical evidence: only small experimental studies
3.1 Rapamycin alone has not been proven to treat depression

There are no large randomized trials showing rapamycin works as a standalone antidepressant.

Most human research instead studies rapamycin combined with ketamine.

3.2 Key randomized clinical trial: rapamycin + ketamine

This is the most important human evidence.

Study design

Depressed patients randomized to:

rapamycin pretreatment + ketamine

placebo pretreatment + ketamine

Main findings

Rapamycin did NOT block ketamine’s antidepressant effect at 24 hours.

Surprisingly, rapamycin prolonged ketamine’s antidepressant effects over 2 weeks.

Response rate at 2 weeks:

Rapamycin + ketamine: 41%

Placebo + ketamine: 13%

Researchers concluded:

Rapamycin may help extend the duration of ketamine’s antidepressant benefit.

Important:
This is preliminary evidence requiring replication.

4) Possible mechanisms being investigated

Researchers propose several hypotheses.

A) Anti-inflammatory effects

Depression is increasingly linked to chronic inflammation.
Rapamycin’s immune effects might:

Protect newly formed synapses after ketamine treatment

Reduce relapse risk

B) Autophagy and brain plasticity

Rapamycin increases autophagy (cellular recycling).
This may:

Improve neuronal health

Support long-term synaptic changes

C) Complex role of mTOR

The relationship is complicated:

Reduced mTOR activity is associated with depressive symptoms.

But rapamycin might help through non-mTOR mechanisms (immune/autophagy effects).

5) Safety signals and concerns

Some real-world evidence raises caution.

A study of transplant patients found:

Rapamycin users had more psychiatric disorders such as adjustment disorder.

This does not prove causation, but highlights risks.

Rapamycin side effects include:

Immunosuppression

infection risk

metabolic changes

This makes routine psychiatric use challenging.

6) Current scientific consensus

What experts generally agree on:

Supported

mTOR is an important depression pathway.

Rapamycin is a valuable research tool.

It may help extend ketamine’s effects (preliminary evidence).

Not supported

Rapamycin as a standalone antidepressant.

Clinical use outside research settings.

Bottom line

Does rapamycin treat depression?

Animal studies: promising.

Human trials: very limited.

Best evidence: may prolong ketamine’s antidepressant effect.

No proof it works by itself.

Not an approved treatment.

Overall: rapamycin is an experimental research avenue, not a depression treatment